Priority Medicines for Europe and the World 2013 Update. Chapter 2 - Background to the 2013 Project
(2013; 12 pages)


Since well before the publication of the 2004 Priority Medicines Report, the goal of biomedical technology companies has been to conduct research and commercialize products in a stable, predictable operating environment that encourages and rewards innovation. However, various pressures currently being placed on pharmaceutical companies can have a negative impact on innovation. It appears that these pressures have been increasing since 2004. The financial investment required for pharmaceutical development has increased, threatening to make the development of new medicines increasingly unaffordable for companies, payers and patients...

Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 29 octobre 2018